Latest Insulin therapy Stories
JERUSALEM, November 15, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double-blind study conducted in 29 patients with Type II diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes. Results were presented by the company's Chief Scientific Officer, Dr. Miriam...
DANBURY, Conn., Nov. 12, 2010 /PRNewswire/ -- Scientists from Biodel Inc. (Nasdaq: BIOD) reported new findings from the company's Linjeta(TM), insulin glargine, "smart" basal insulin and stabilized glucagon development programs in poster presentations yesterday and today at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD. Dr. Frank Flacke presented results of a Phase 1 single-center, double-blind, randomized crossover trial in 13 subjects with type 1 diabetes who received a...
DALLAS and NEW YORK, Nov. 11, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that it will be presenting a poster today at the 10th Annual Diabetes Technology Meeting, entitled, "Preclinical Studies with Cobalamin(TM) Nanoparticles for Oral Drug Delivery of Insulin." The poster reviews the...
JERUSALEM, October 26, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its work entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," will be presented at the Tenth Annual Meeting of the Diabetes Technology Society, to be held in Bethesda, Maryland this November. "The selection of Oramed as one of...
PRINCETON, N.J., Oct. 22 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and the Entertainment Industries Council (EIC) are launching a collaborative project to enhance dialogue among local diabetes experts, policy makers and the media to improve public awareness of the key issues associated with diabetes management. (Logo: http://photos.prnewswire.com/prnh/20020404/NVOLOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO ) The locally-based effort will...
Blood sugar levels improved for those paired up for support with peersPhone calls with a peer facing the same self-management challenges helped diabetes patients manage their conditions and improved their blood sugar levels better than those who used traditional nurse care management services alone, according to research from the University of Michigan Health System.The findings, published Oct. 19 in the Annals of Internal Medicine, showed the peer partner program resulted in lower glycated...
Blood sugar levels improved for those paired up for support with peers ANN ARBOR, Mich., Oct. 18 /PRNewswire-USNewswire/ -- Phone calls with a peer facing the same self-management challenges helped diabetes patients manage their conditions and improved their blood sugar levels better than those who used traditional nurse care management services alone, according to research from the University of Michigan Health System. The findings, published Oct. 19 in the Annals of Internal Medicine,...
Insulin resistance, a condition in which insulin produced by the body becomes less effective in reducing blood glucose levels, appears to be associated with an increased risk of stroke in individuals without diabetes, according to a report in the October issue of Archives of Neurology, one of the JAMA/Archives journals.Insulin resistance originates from several factors, including genetics, a sedentary lifestyle and obesity, according to background information in the article. The condition...
PRINCETON, N.J., Oct. 4 /PRNewswire/ -- Novo Nordisk, a global healthcare company and leader in diabetes care, today announced a $73 million expansion of its Clayton, NC manufacturing facility to accommodate increased production capacity for the Company's insulin delivery devices. The initial expansion will create 205 new jobs, including 85 in the Novo Nordisk Clayton facility, which currently produces a number of products, including the Levemir® FlexPen® (insulin detemir [rDNA...
PRINCETON, N.J., Oct. 4 /PRNewswire/ -- Novo Nordisk announced today that Mark Sides from Longview, Texas is the grand prize winner of the Where Have You Flexed online photo contest. The contest was designed to help change the way people think about taking insulin, and asked those who use Novo Nordisk pre-filled insulin pens to submit photos of unique and interesting places they have gone with their device. Mark received the most votes for a photo of himself with his NovoLog®...
Latest Insulin therapy Reference Libraries
Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...
